IKur antagonists (Bristol-Myers Squibb/ICAgen)

N/A

Report date: 2025/03/20 20:00:06
NME

Base Information

Drug NameIKur antagonists (Bristol-Myers Squibb/ICAgen)
Drug Alias Nameantiarrhythmics (Bristol-Myers Squibb/ICAgen)ion channel modulators (BMS/ICAgen)potassium channel antagonists (BMS/ICAgen)IKur antagonists (BMS/ICAgen)ion channel modulators (Bristol-Myers Squibb/ICAgen)
ClassificationSmall molecules > Heterocyclic drugs
Mechanisms of ActionVoltage-gated potassium channel subunit Kv1.5 blockers
TargetsVoltage-gated potassium channel subunit Kv1.5
Therapy Area/IndicationsArrhythmias, Cardiac
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPending (Phase 1 Clinical)
Highest Status in ChinaN/A
Originator CompaniesIcagen Inc
China Registration ClassN/A

Develop Information

Active CompaniesN/A
Inactive CompaniesIcagen IncBristol-Myers Squibb Company
Active IndicationsN/A
Inactive IndicationsArrhythmias, Cardiac

Other Information

ATC CodeN/A
Related LinksN/A